Spire Healthcare Group (LON:SPI) Receives Overweight Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their overweight rating on shares of Spire Healthcare Group (LON:SPI) in a report published on Thursday, Marketbeat Ratings reports. The brokerage currently has a GBX 344 ($4.28) price objective on the stock.

Separately, Berenberg Bank raised their price objective on shares of Spire Healthcare Group from GBX 286 ($3.56) to GBX 300 ($3.73) and gave the company a buy rating in a research report on Wednesday, April 17th.

Spire Healthcare Group Price Performance

LON SPI opened at GBX 246 ($3.06) on Thursday. The firm has a market capitalization of £994.16 million, a price-to-earnings ratio of 3,514.29, a price-to-earnings-growth ratio of 1.06 and a beta of 0.99. The company has a 50 day simple moving average of GBX 237.75 and a 200-day simple moving average of GBX 229.21. The company has a debt-to-equity ratio of 170.37, a current ratio of 0.69 and a quick ratio of 0.74. Spire Healthcare Group has a 52-week low of GBX 204 ($2.54) and a 52-week high of GBX 321.71 ($4.00).

Spire Healthcare Group Increases Dividend

The firm also recently disclosed a dividend, which will be paid on Friday, June 21st. Investors of record on Thursday, May 23rd will be given a dividend of GBX 2.10 ($0.03) per share. This represents a yield of 0.89%. The ex-dividend date of this dividend is Thursday, May 23rd. This is a positive change from Spire Healthcare Group’s previous dividend of $0.50. Spire Healthcare Group’s dividend payout ratio (DPR) is presently 4,285.71%.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.